For the roughly 700,000 people living with a functioning kidney transplant worldwide, receiving a new organ is not the finish line — it is the starting point of a different and often underappreciated medical challenge. Despite restoring kidney function, transplantation introduces a distinct cardiovascular risk profile that current clinical guidelines are poorly equipped to address, leaving a large and growing patient population in a management gap.

This review, published in Nephrology, Dialysis, Transplantation, maps the overlapping risk architecture that drives persistent cardiovascular disease in kidney transplant recipients. While transplantation does reduce uremic toxin burden and improves several cardiometabolic markers, it simultaneously introduces immunosuppressive regimens that elevate blood pressure, impair glucose metabolism, and promote dyslipidemia. Post-transplant diabetes mellitus emerges as a particularly consequential complication, compounded by chronic low-grade inflammation that does not resolve with restored filtration. The result is a cardiovascular burden spanning coronary artery disease, heart failure, valvular pathology, and peripheral artery disease. Critically, the review identifies that standard cardiovascular risk calculators — designed for general populations — systematically underestimate risk in transplant recipients because they omit transplant-specific variables entirely. Emerging drug classes including SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists are highlighted as promising but unvalidated in dedicated transplant trials.

The core limitation exposed here is structural: transplant medicine has historically prioritized rejection prevention over cardiovascular optimization, and the evidence base reflects that imbalance. Most pharmacological guidance is extrapolated from non-transplant populations — a scientifically shaky foundation for a patient group with fundamentally altered physiology. The added signal on sex-based disparities in both transplant access and post-transplant outcomes underscores that this is not a monolithic population. For health-conscious adults, this review reinforces that organ transplantation trades one set of risks for another, and that long-term survival gains hinge on aggressive, transplant-specific cardiovascular surveillance rather than standard preventive protocols.